A billion-dollar deal to expand the data flywheel
- Tempus sells genomic tests and turns de-identified clinical and molecular data into paid products for drug companies.
- In July 2026, Tempus announced a proposed $1.5 billion acquisition of Personalis to accelerate its diagnostics expansion.
- In Q1 2026, Genomics produced $261.1 million of revenue, about 75% of total company revenue.
- Data and Services grew faster in Q1 2026, rising 41% year over year to $87.0 million.
- The main tension is price and proof. Tempus is still losing money under GAAP and must manage new debt and legal risks.
Data moat meets aggressive expansion
Tempus is trying to build a flywheel in precision medicine. It runs diagnostic tests for patients, cleans and de-identifies the data, then sells data and AI services to drug companies. The bull case is that each new test makes the dataset more useful, and each new pharma deal makes the business more valuable.
The company is now using acquisitions to scale that flywheel faster. In July 2026, Tempus announced an agreement to buy Personalis for an enterprise value of $1.5 billion. Combined with earlier large strategic collaborations with Merck and Gilead, the Data and Services story feels more tangible than ever.
The financial turn is still a work in progress. Q1 2026 revenue grew 36% year over year to $348.1 million, and adjusted EBITDA improved to negative $2.8 million from negative $16.2 million a year earlier. Management points to about $65 million of positive adjusted EBITDA for full-year 2026, though the company just issued $460 million in new convertible notes to fund its plans.
The bear case revolves around the path to actual free cash flow and a growing list of overhangs. Tempus reported a Q1 2026 net loss of $125.9 million. The stock also needs to justify a rich valuation while the company faces integration risks from the Personalis deal, a Civil Investigative Demand regarding billing practices, and a new privacy class action in Illinois.
Tests feed the dataset
Tempus first makes money from diagnostic testing. Doctors and hospitals order genomic and other molecular tests to help guide care. Ambry Genetics added hereditary and genetic screening, which broadened the testing base beyond oncology.
The second money stream is data. Tempus structures and de-identifies clinical and molecular records, then licenses the data and related AI tools to pharmaceutical and biotech companies. These customers use the products for research, drug development, and clinical trial matching.
This model can be powerful because one patient record can create revenue more than once. The test can be paid for when it is run, and the de-identified data can later support data licensing or services. That is why the Data and Services segment matters so much, even though it was only about 25% of Q1 2026 revenue.
The model breaks if payers cut test reimbursement, if privacy rules limit data use, if pharma customers slow new deals, or if the data does not keep proving useful in drug development. Tempus also needs to show that inorganic growth from acquisitions can eventually lead to GAAP net income.
Four ways to use the data
Oncology and molecular genomics
These are next-generation sequencing, PCR profiling, and other molecular tests sold to healthcare providers. They drive volume and feed the main dataset.
Ambry hereditary genetics
Ambry added hereditary and genetic screening in areas such as pediatrics, rare disease, cardiology, reproductive health, and immunology.
Insights data licensing
Insights gives pharma and biotech customers access to de-identified clinical and molecular data for research. Management has pointed to strong growth and rising contract value in this line.
Trials and AI applications
Trials uses AI to help match patients to clinical trials, while AI applications support diagnostic and clinical decisions. Paige.AI added digital pathology to this mix.
Q1 mix still test-heavy
Segment mix is from the three months ended March 31, 2026. Genomics was about three quarters of revenue, while Data and Services was about one quarter, even though Data and Services grew faster.
What could break
Personalis integration and dilution
High impact · Medium oddsThe proposed $1.5 billion acquisition of Personalis adds significant integration risk. The deal could also dilute existing shareholders depending on the final cash and stock mix used at closing.
Adjusted profit may not become real profit
High impact · Medium oddsTempus is close to adjusted EBITDA profit, but it still reported a Q1 2026 net loss of $125.9 million. The company has a heavy debt load and a $2.4 billion accumulated deficit as of December 31, 2025.
Convertible debt burden
Medium impact · Medium oddsTempus recently added a new $460 million 0.00% convertible note due 2032 to its existing debt stack. These notes introduce future debt service and possible share dilution if the stock price hits conversion thresholds.
Billing investigation overhang
High impact · Medium oddsTempus received a Civil Investigative Demand from the U.S. Attorney's Office for the Eastern District of New York on March 4, 2024. It relates to the False Claims Act and the Medicare 14-Day Rule. The possible cost or operating impact is still unknown.
Genomics reimbursement pressure
High impact · Medium oddsGenomics was about 75% of Q1 2026 revenue, so payment rates matter a lot. If Medicare, private insurers, or hospitals pay less or slow approvals, test revenue and gross profit could suffer.
Privacy lawsuits and data access
High impact · Low oddsThe company faces a new class action lawsuit filed in February 2026 alleging violations of the Illinois Genetic Information Privacy Act. If privacy rules tighten or legal outcomes restrict data use, the data flywheel could slow.
In one breath
What does Tempus AI actually do?
Tempus runs genomic and other diagnostic tests, mainly for healthcare providers. It then structures de-identified patient data and sells data, analytics, and AI tools to drug companies.
Why is Tempus acquiring Personalis?
Tempus announced a $1.5 billion proposed acquisition of Personalis in July 2026 to expand its diagnostic footprint and add new, valuable datasets to its precision medicine platform.
Is Tempus profitable?
Not under GAAP. While management guides to about $65 million of positive adjusted EBITDA for 2026, the company still reported a net loss of $125.9 million in Q1 2026.
What is the biggest risk for TEM stock?
The biggest risk is paying a high price before the company proves durable cash flow. Investors also need to watch acquisition integration risks, debt levels, the ongoing billing investigation, and fresh genetic privacy lawsuits.
